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Abstract
Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), particularly
in NOTCH1-mutated patients. We provide first evidence that the Notch ligand DLL4 is a potent stimulator of Notch signaling in
NOTCH1-mutated CLL cells while increases cell proliferation. Importantly, DLL4 is expressed in histiocytes from the lymph
node, both in NOTCH1-mutated and -unmutated cases. We also show that the DLL4-induced activation of the Notch signaling
pathway can be efficiently blocked with the specific anti-Notch1 antibody OMP-52M51. Accordingly, OMP-52M51 also
reverses Notch-inducedMYC, CCND1, and NPM1 gene expression as well as cell proliferation in NOTCH1-mutated CLL cells.
In addition, DLL4 stimulation triggers the expression of protumor target genes, such as CXCR4, NRARP, and VEGFA, together
with an increase in cell migration and angiogenesis. All these events can be antagonized by OMP-52M51. Collectively, our
results emphasize the role of DLL4 stimulation in NOTCH1-mutated CLL and confirm the specific therapeutic targeting of
Notch1 as a promising approach for this group of poor prognosis CLL patients.
Introduction
Activating mutations in NOTCH1 have emerged as one of
the most frequent somatic alterations in chronic lympho-
cytic leukemia (CLL), affecting up to 10–15% of patients at
diagnosis [1, 2]. Clinically, NOTCH1-mutated patients have
features associated with adverse prognosis and high risk of
transformation [2–4]. The majority of these mutations
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abrogate the PEST domain and generate a truncated protein
that accumulates in the cell and activates downstream sig-
naling [2]. More recently, recurrent mutations in the non-
coding 3’UTR of NOTCH1 have been identified in ~3% of
CLL patients, which cause aberrant splicing events that lead
to the loss of the PEST domain and increase Notch1 activity
[5]. The functional effect of the different types of NOTCH1
mutations has been extensively studied in T-acute lym-
phoblastic leukemia (T-ALL), where most Notch1 altera-
tions affect the heterodimerization domain of the receptor
and lead to a constitutive ligand-independent Notch acti-
vation [6]. In contrast, both PEST and 3’UTR mutations
described in CLL are considered as weak NOTCH1 muta-
tions, not oncogenic by themselves, and are ligand-
dependent [5, 6].
Jagged and Delta-like ligands interact with Notch
receptors to induce their cleavage and nuclear translocation
of the intracellular domain. Once in the nucleus, Notch
activates the transcription of target genes including HES1
and MYC. Notch1 target genes regulate key biological
processes such as development, cell differentiation, cell-fate
decisions, proliferation, and apoptosis [7]. In CLL, auto-
crine and paracrine mechanisms of Notch activation have
been suggested, as both tumor CLL lymphocytes as well as
cells from the microenvironment express Notch ligands,
particularly Jagged1 and Jagged2 [8, 9]. However, knowl-
edge about the role of Delta-like ligands in CLL is still
limited. Although NOTCH1 mutations have a prominent
role in the pathogenesis of CLL, alternative nonmutational
mechanisms of NOTCH1 activation have been recently
described in CLL [10], indicating that the constitutive
activation of the pathway in this leukemia is more frequent
than it was first estimated by the incidence of the main
recurrent genetic lesions. For this reason, targeting Notch
signaling has emerged as a promising therapeutic strategy
for CLL, with the hypothesis that its inhibition might also
provide an improvement in the efficacy of the standard
chemotherapy. Our group previously reported the antitumor
effect of the γ-secretase inhibitor (GSI) PF-03084014 in
combination with fludarabine in CLL cells carrying
NOTCH1 mutations [11]. Similarly, a marked in vitro
resistance to drug-induced apoptosis in CLL cells harboring
NOTCH1 mutations has been reported, which may be
abrogated by GSI [8]. Moreover, the combination of PF-
03084014 and fludarabine is able to reduce angiogenesis
and CXCL12-induced responses in NOTCH1-mutated CLL
cells, in particular those related to tumor migration and
invasion [11]. Although preclinical and clinical data using
GSIs are encouraging, the main limitations of GSI treatment
include nonselectivity and gastrointestinal toxicity [12]. In
the last years, antibodies against the specific Notch recep-
tors have been developed, with the idea of avoiding these
undesirable side effects [12]. Targeting the individual
Notch1 receptor has shown promising preclinical results in
T-ALL [13–15], indicating the need to explore this ther-
apeutic strategy in other models of lymphoid malignancies.
In this context, the aim of the present study was to define the
role of Delta-like ligand stimulation in NOTCH1-mutated
CLL cells as well as to explore the therapeutic disruption of
this signaling with a specific anti-NOTCH1 antibody.
Results
DLL4 is a potent stimulator of Notch signaling and
proliferation in NOTCH1-mutated CLL
To evaluate the effect of Notch ligands in CLL, we first
stimulated primary CLL cells with the recombinant ligands
Jagged1, Jagged2, DLL1, and DLL4 at 10 μg/mL. To obtain
a potent activation of Notch1 the excess of soluble ligand
was not removed, indicating that most of the agonistic effect
was due to the remaining soluble ligand. After 24 h we
analyzed the expression of the active form of Notch1 by
Western blot. As shown in Fig. 1a, cleaved Notch1 was
detected at basal levels in cells from NOTCH1-mutated
cases, and, after stimulation with soluble Notch ligands, this
activated form of Notch1 increased particularly after Delta-
like ligand stimulation. In NOTCH1-unmutated CLL, as
previously described [2], no basal cleaved Notch1 was
detected, although DLL4 and DLL1 were able to activate
Notch1. To further confirm the potent stimulation of Notch
signaling by Delta-like ligands in an immobilized model,
we cocultured primary CLL cells with the stromal cells OP9
expressing the different human Notch ligands Jagged1
(OP9-JAG1), DLL1 (OP9-DLL1), and DLL4 (OP9-DLL4).
After 24 h, NOTCH1-mutated CLL cells cocultured with
OP9-DLL4 showed the strongest activation of Notch1 in
comparison with the other ligands (Fig. 1b), suggesting that
DLL4 could be the main ligand responsible for Notch
activation in CLL both under soluble and immobilized
conditions.
Next, we sought to determine whether Notch stimulation
had a functional relationship with CLL proliferation. To this
aim, we used a CFSE-based assay to monitor the pro-
liferation of CLL cells after a 6-days exposure with CpG
oligodeoxynucleotide (ODN-2006) and IL-15, as both fac-
tors collaborate in promoting in vitro CLL growth [16]. We
showed that proliferation induction resulted to be significant
only in NOTCH1-mutated CLL cells stimulated with Delta-
like ligands, especially with DLL4 (p= 0.001), consistent
with cleaved Notch1 expression (Fig. 1c). Interestingly, this
functional effect was specific for NOTCH1-mutated cells
and was almost undetected in unmutated cases. All these
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results indicated a particular sensitivity of CLL cells to
DLL4 stimulation.
DLL4 is expressed in the CLL lymph node
In view of the remarkable in vitro effect of DLL4 in
NOTCH1-mutated CLL, we sought to characterize which
cells could express this ligand and trigger the activation of
Notch in vivo. We analyzed the expression of DLL4 in the
different cellular populations present in lymph nodes (LN)
infiltrated by CLL, using immunofluorescence staining and
confocal microscopy and tonsil biopsies as controls. In
tonsils, we observed coexpression of DLL4 with the
monocytic marker CD68 in some histiocytes (Fig. 2).
Although tissue architecture is completely effaced in CLL
LN, we found that the Notch ligand DLL4 was widely
expressed in the vascular endothelium (Supplemental Fig.
1) and, importantly, it was also expressed by some CD68+
cells in both NOTCH1-mutated and -unmutated cases (Fig.
2). All these results suggested that DLL4 is expressed in the
lymph node CLL compartment, and could thus provide a
specific niche for Notch activation.
The anti-NOTCH1 antibody OMP-52M51 inhibits
DLL4-induced Notch activation in CLL
To evaluate the potential therapeutic targeting of ligand-
dependent Notch signaling in CLL, we considered our
functional results above showing that DLL4 promoted
effective Notch activation in NOTCH1-mutated CLL cells.
Thus, primary CLL cells were treated for 2 h with the
specific anti-NOTCH1 antibody OMP-52M51 before
DLL4 stimulation. In all the experiments with OMP-
52M51, an isotype control was added to the untreated
condition. Then we monitored the modulation of cleaved
Notch1 by Western blot after 24 h. In contrast to what we
observed when CLL cells were stimulated by DLL4 alone,
the addition of OMP-52M51 impaired Notch1 DLL4-
dependent stimulation. This effect was more pronounced
in cells from NOTCH1-mutated cases but was also observed
in NOTCH1–unmutated ones (Fig. 3a). The treatment with
OMP-52M51 only reversed the fraction of cleaved Notch1
increased with the ligand but not the basal active Notch1.
Moreover, we analyzed the levels of Notch1-direct target
genes after OMP-52M51 treatment and ligand stimulation.
Fig. 1 DLL4 is a potent stimulator of Notch pathway and proliferation
in NOTCH1-mutated CLL. Cells from NOTCH1-mutated and
-unmutated CLL cases were stimulated with Jagged1 (JAG1), Jagged2
(JAG2), DLL1, and DLL4 (10 μg/ml) ligands (a) or stromal cells OP9-
JAG1, OP9-DLL1, and OP9-DLL4 (b). Cleaved Notch1 was analyzed
by Western blot at 24 h and densitometrically quantified. β-Actin was
probed as a loading control. Representative cases are shown (CLL 6, 9,
and 18). c CFSE-labeled CLL cells were incubated with ODN-2006
and IL-15 together with JAG1, JAG2, DLL1, or DLL4. Reduction of
CFSE fluorescence in viable CLL cells was quantified after 6 days by
flow cytometry. Graph shows the percentage of cell proliferation
induction of each ligand with respect to the unstimulated control.
Mean ± SEM of all the samples analyzed (n= 6 NOTCH1-mutated and
n= 6 NOTCH1-unmutated). **p < 0.01; *p < 0.05, ns not significant
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Using quantitative PCR, we found that DLL4 increased the
mRNA levels of HES1 and DTX1 specifically in NOTCH1-
mutated cases, and OMP-52M51 abrogated almost com-
pletely this effect after 24 h of treatment (Fig. 3b). In con-
trast, no transcriptional effect of DLL4 was observed in
NOTCH1-unmutated cases either with or without antibody
treatment.
All these results indicated that the activation of Notch
signaling pathway induced by DLL4 in NOTCH1-mutated
CLL is stronger than in unmutated cases and could be
blocked with a specific Notch1 receptor antibody.
OMP-52M51 inhibits DLL4-induced CLL proliferation
Since one of the most impressive effects of
DLL4 stimulation was the induction of cell proliferation in
NOTCH1-mutated CLL, we were interested in exploring the
ability of OMP-52M51 to antagonize this effect. Using a
CFSE-based assay in long-term cultures, we found that the
DLL4-induced increase in cell proliferation in NOTCH1-
mutated CLL cells was partially but significantly blocked
by OMP-52M51 (p < 0.05, Fig. 4a). According to these
results, we investigated the modulation of three genes
known to play a key role in the control of cell proliferation,
MYC, NPM1, and CCND1, which have been functionally
related to Notch pathway in leukemic cells [10, 17, 18].
Thus, after 72 h, DLL4 significantly upregulated MYC (p <
0.05) and NPM1 (p < 0.05) in NOTCH1-mutated CLL cells,
and CCND1 showed a similar trend (Fig. 4b). Consistently,
OMP-52M51 inhibited the DLL4-induced MYC and NPM1
(p < 0.05), and tended to reduce CCND1 gene expression,
specifically in CLL cells carrying NOTCH1 mutation (Fig.
4b). These results suggested that Notch1 signaling upre-
gulates cell proliferation including MYC gene expression
and that this axis could be therapeutically targeted with an
anti-Notch1 antibody.
DLL4 stimulation of NOTCH1-mutated CLL cells
induces CXCR4 expression and migration that can
be inhibited by OMP-52M51
Previous work reported that anti-Notch treatment effectively
prevents multiple myeloma cell migration by reducing
CXCR4 expression at transcriptional level [19]. Given the
importance of CXCR4/CXCL12 in CLL biology, we ana-
lyzed the effect of Notch ligand stimulation and its ther-
apeutic targeting in this axis. With this objective, we
quantified the gene expression levels of CXCR4 by quan-
titative PCR and protein levels by flow cytometry and
assayed CLL cell migration toward CXCL12 after 48 h of
incubation with OMP-52M51 and ligand stimulation.
Exposure to DLL4 upregulated CXCR4 mRNA expression
as well as protein levels specifically in NOTCH1-mutated
CLL cells (p < 0.05), together with an induction of the
CXCL12-induced migratory capacity of these cells (Fig.
5a–c). Importantly, the anti-Notch1 antibody significantly
reversed both CXCR4 gene expression levels
(p < 0.01) and chemotaxis in DLL4-stimulated NOTCH1-
mutated CLL (p < 0.05).
Furthermore, in addition to CXCL12-induced chemo-
taxis, we also showed that DLL4 increased CLL cell
migration toward CXCL13, another chemokine known to
play a role on CLL pathogenesis [20], and similarly to
CXCL12, OMP-52M51 blocked this induction in
NOTCH1-mutated CLL (n= 6; Fig. 5d).
DLL4 increases angiogenic factors in NOTCH1-
mutated CLL that can be blocked by OMP-52M51
Notch pathway is involved in physiological as well as tumor
angiogenesis [21]. Therefore, we sought to explore the
functional link between Notch1 and angiogenesis in CLL.
To this aim, we carried out HUVEC tube formation assays
with the supernatants from primary CLL cells exposed to
DLL4 in the presence or absence of OMP-52M51. Super-
natants from NOTCH1-mutated cells stimulated with DLL4
Fig. 2 DLL4 is expressed in CLL lymph nodes. Immunofluorescence
staining of tonsils and CLL LN with anti-CD68 (green) and anti-DLL4
(red). Nuclei were stained with Topro-3 (blue). White arrows indicate
representative CD68+/DLL4+ cells. Pictures were taken at ×63
magnification in a confocal microscope. Images from a representative
case per group are shown (CLL 11 and 19)
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had a proangiogenic effect increasing the number of branch
point of HUVEC cells, whereas OMP-52M51 hampered
this effect (p < 0.05). Again, no effect on NOTCH1-unmu-
tated cases was observed, irrespective of the ligand or
antibody exposure (Fig. 6a). To identify possible mediators
of this effect, we explored the mRNA expression modula-
tion of two proangiogenic candidate genes for which a
functional link with Notch has been proposed: NRARP and
VEGF [22–24]. Using quantitative PCR, we showed a
significant upregulation of NRARP and VEGFA levels (p <
0.05), which was blocked by OMP-52M51 treatment in
NOTCH1-mutated CLL cells (Fig. 6b, c). Altogether, these
results suggest a functional transcriptional link between
Notch1 signaling and aggressiveness-related protumor
processes in CLL and that may be disrupted by a Notch-
targeted strategy.
Discussion
NOTCH1 mutations in CLL are activating events that
increase the stability of Notch1 intracellular domain [2].
However, these mutations have a weak transforming effect
and are expected to be dependent on the presence of Notch
ligands in the microenvironment to trigger and maintain a
constitutive Notch1 activation. Accordingly, in vitro studies
have shown that crosstalk between tumor CLL cells and
accessory cells is required to maintain Notch signaling [8].
However, the microenvironmental cell components as well
as the ligands that lead to Notch1 activation in CLL are not
yet well established. On the other hand, targeting the con-
nection between the ligand- and the receptor-presenting cell
has emerged as a new therapeutic opportunity that also
needs to be explored, in particular for the high-risk
NOTCH1-mutated CLL patients. In the present work, we
have attempted to address both questions using primary
CLL cells from both NOTCH1-mutated and -unmutated
cases. First, we showed that DLL4 was a potent stimulator
of Notch1 signaling mainly in NOTCH1-mutated CLL cells,
leading to the activation of some protumor genes and
inducing processes that confer aggressiveness to the tumor,
such as cell proliferation, migration, and angiogenesis.
Second, we identified for the first time an efficient and
specific strategy to target this ligand-induced Notch acti-
vation with an anti-Notch1 antibody. Our results pointed
out that the functional effects of the DLL4-induced stimu-
lation were specific of cells carrying NOTCH1 mutations
and barely occurred in unmutated cases without basal
Fig. 3 OMP-52M51 inhibits DLL4-induced Notch activation in CLL.
Primary cells from NOTCH1-mutated and NOTCH1-unmutated CLL
cases were pretreated for 2 h with OMP-52M51 before
DLL4 stimulation (4 μg/mL) for 24 h. a Cleaved Notch1 was assessed
by Western blot and densitometrically quantified. β-Actin was probed
as a loading control. Representative cases are shown (CLL 2, 8, and
18). b Gene expression analysis by quantitative real time PCR of
HES1 and DTX1. mRNA relative levels are given as arbitrary units,
using untreated condition as a reference. Control: isotype control. Bars
represent the mean ± SEM of NOTCH1-mutated (n= 5) and -unmu-
tated (n= 5) CLL cases. p < 0.05
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cleaved Notch1. We hypothesized that in NOTCH1-unmu-
tated cells the signaling would not be sustained enough to
have a substantial transcriptional and functional impact, as
the wild type Notch1 protein has a rapid turnover [25].
Accordingly, NOTCH1 mutations in the PEST domain have
been suggested to increase the cleaved Notch1 half-life [2].
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The effect that DLL4 could have in CLL with alternative
nonmutational NOTCH1 activation [10] needs further
validation.
We first investigated the stimulation of CLL cells with
the different Notch ligands Jagged1, Jagged2, DLL1, and
DLL4. Our results highlighted an important role for the
Delta-like ligands DLL4 and DLL1 in CLL, being DLL4
the most potent stimulator of Notch signaling in NOTCH1-
mutated CLL cells. Interestingly, this DLL4 stimulation was
accompanied by a strong increase in CLL cell proliferation
and was specific for mutated cases. However, the stimula-
tion induced by DLL1 was also remarkable and its potential
effect on CLL Notch1 stimulation cannot be rule out. DLL1
and DLL4 are structurally related and could promote a
similar downstream signaling, although it has been reported
that the affinity of DLL4 for Notch1 is more than 10-fold
tighter than that of DLL1 [26].
In contrast to what happens in other cellular models, in
which soluble Notch ligands have an antagonistic effect
[27–30], in CLL we showed that both soluble and immo-
bilized DLL4 had an activating effect in Notch1 signaling.
It is currently unknown whether any form of soluble
(nonmembrane bound) Notch ligand is physiologically
present or relevant in the CLL microenvironment. Further-
more, we provided first evidence that DLL4 was expressed
in the lymph node CLL compartment, where it could pro-
mote Notch activation in vivo. In particular, DLL4 was
highly expressed in the vascular endothelium, as described
in other tumor models [31], as well as in accompanying
histiocytes. Thus, the stimulation of Notch induced by the
DLL4 in CLL could be through the interaction of CLL cells
with surrounding cells from the microenvironment. These
results agree with previous data suggesting that the Notch1
pathway is strongly activated in CLL LN [5, 8], which
represent a relevant proliferative niche for the tumor cells
[32]. Monocytes/macrophages play a key role in CLL
development and progression through their reciprocal
molecular interactions [33, 34]. Our results indicate that the
potential role of macrophages in the stimulation of Notch
signaling by DLL4 needs further validation. Accordingly, it
has been recently described that in bone marrow the
monocyte/macrophage- CLL cells crosstalk upregulates
NOTCH1 and CXCR4, among other genes, suggesting that
macrophage targeting can be therapeutically exploited in
CLL [35].
Among Notch targeted therapies, GSIs have been the
most broadly assessed drugs in different malignancies. In
CLL, first attempts to block in vitro Notch1 signaling were
Fig. 4 OMP-52M51 inhibits DLL4–induced proliferation. a CFSE-
stained CLL cells were pretreated for 2 h with OMP-52M51 before
DLL4 stimulation (4 μg/mL) for 6 days. Reduction of CFSE fluores-
cence in viable CLL cells was quantified by flow cytometry. Graph
shows the percentage of cell proliferation induction with respect to the
unstimulated control. Mean ± SEM of all the samples analyzed. Bot-
tom panel shows the histograms of CFSE staining in representative
CLL cases (CLL 2 and 15). b Cells from NOTCH1-mutated and
NOTCH1-unmutated CLL cases were pretreated for 2 h with OMP-
52M51 before DLL4 stimulation (4 μg/mL) for 72 h. Gene expression
of MYC, CCND1, and NPM1 was analyzed by quantitative real time
PCR. mRNA relative levels are given as arbitrary units, using
untreated cells as a reference. Control: isotype control. Bars represent
the mean ± SEM of NOTCH1-mutated (n= 6) and -unmutated (n= 4)
CLL cases. p < 0.05
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based on the use of these inhibitors, alone or in combination
with chemotherapy [8, 11]. Although these preclinical data
showed promising results in CLL NOTCH1-mutated cells,
the nonselectivity and gastrointestinal toxicity of GSIs
observed in other types of tumors emphasized the need to
explore more selective strategies to inhibit Notch1. In this
context, specific antibodies against the individual Notch
receptors have been developed [14, 15]. Among them,
OMP-52M51 is an anti-human Notch1 monoclonal anti-
body that showed encouraging antitumor efficacy in xeno-
graft models of T-ALL [13]. In NOTCH1-mutated cells, we
showed that OMP-52M51 efficiently inhibited soluble
DLL4-induced Notch stimulation as well as cell prolifera-
tion. Accordingly, OMP-52M51 also reversed the Notch-
induced MYC, CCND1, and NPM1 gene expression. These
three genes are known to play a functional role in the control
of cell proliferation in leukemic cells [10, 17, 18]. In parti-
cular, MYC and NPM1 have been involved in the pro-
liferation advantages of NOTCH1-mutated CLL. MYC is a
direct NOTCH1 target and a central oncogene involved in
CLL progression [36], as occurs in T-ALL [37]. NPM1 has
been identified, together with other genes related to protein
biosynthesis, as a targetable MYC-related gene that is over-
expressed in NOTCH1-mutated CLL cells [18]. However,
these conclusions are limited as a nonphysiological situation
of our soluble ligand stimulation system cannot be ruled out.
We also confirmed a functional relationship between
Notch1 signaling and the microenvironmental processes
related to CLL aggressiveness such as cell migration and
angiogenesis, a link that was previously suggested by our
group [11]. This axis could be particularly relevant in
NOTCH1-mutated cases, as they have been shown to be
associated with disease progression and transformation to
more aggressive forms [4]. In this line, Notch1 signaling
contributes to CCL19-driven migration of CLL cells to
tissues [38]. The CXCR4/CXCL12 pathway is also
fundamental for CLL homing and CXCR4 expression has
been related to an increased risk for lymphoid organ infil-
tration and poor outcome [39]. In this context, CXCR4 has
also emerged as a novel NOTCH1 target in CLL [10].
Remarkably, we reported that soluble DLL4-induced
CXCR4 expression and migration were both inhibited by
OMP-52M51 in NOTCH1-mutated CLL cells. In agree-
ment, Notch inhibition effectively prevents multiple mye-
loma cell migration by reducing CXCR4 expression at the
transcriptional level [19]. However, as the increase of
Fig. 5 OMP-52M51 inhibits DLL4-induced CXCR4 expression and
migration. Primary cells from NOTCH1-mutated and NOTCH1-
unmutated CLL cases were pretreated for 2 h with OMP-52M51 before
DLL4 stimulation (4 μg/mL) for 48 h. a CXCR4 expression was ana-
lyzed by quantitative real time PCR. mRNA relative levels are given as
arbitrary units, using untreated cells as a reference. b CXCR4
expression was analyzed by flow cytometry (n= 4 NOTCH1-mutated
cells; n= 4 NOTCH1-unmutated cells). CXCR4 expression levels are
showed based on the median fluorescence intensity (MFI) on viable
cell population, using untreated cells as a reference. c Samples were
assayed for chemotaxis toward CXCL12 (200 ng/ml). Migration is
represented as the percentage of migrating cells out of total viable cells
added to the transwell. Control: isotype control. Bars represent the
mean ± SEM of NOTCH1-mutated (n= 8) and -unmutated (n= 4)
CLL cases. *p < 0.05; **p < 0.01. d Samples were assayed for che-
motaxis toward CXCL13 (500 ng/ml). Migration is represented as the
percentage of migrating cells out of total viable cells added to the
transwell. Bars represent the mean ± SEM of NOTCH1-mutated CLL
cases (n= 6). *p < 0.05
Fig. 6 OMP-52M51 inhibits DLL4-induced angiogenesis. Primary
cells from NOTCH1-mutated (n= 6) and NOTCH1-unmutated (n= 4)
CLL cases were pretreated for 2 h with OMP-52M51 before
DLL4 stimulation (4 μg/mL) for 72 h. a Supernatant from CLL cells
was harvested after treatment and added to HUVEC cells for 24 h. The
number of branch points was quantified as the mean of five randomly
chosen fields from each well. Bars represent the mean ± SEM. *p <
0.05. Microscope images (×40 magnification) from a representative
case per condition are shown (CLL 2 and 12). b NRARP and VEGFA
expression was analyzed by quantitative real time PCR. mRNA rela-
tive levels are given as arbitrary units, using untreated cells as a
reference. Control: isotype control
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CXCR4 by DLL4 is relatively modest compared with the
chemotaxis induction, other Notch1-dependent mediators
should not be discarded. In this way, the same effect of
DLL4 and OMP-52M521 was observed in NOTCH1-
mutated cell migration toward CXCL13, suggesting that
Notch1 signaling would lead to a general increase in
NOTCH1-mutated CLL chemotaxis. In parallel, we showed
that supernatants from NOTCH1-mutated CLL cells stimu-
lated with DLL4 increased HUVEC tube formation, whereas
OMP-52M51 was able to block this proangiogenic effect.
This was accompanied by the transcriptional modulation of
the angiogenic factors NRARP and VEGFA. It is well
established that the Notch pathway is involved in physio-
logical as well as tumor angiogenesis [21]. In acute myeloid
leukemia, leukemic cells increased HUVEC tube formation
through the activation of the VEGF and DLL4 pathway [40].
In this sense, our results highlight that in CLL might be also
a link between DLL4 and VEGF, although the proangio-
genic role of other Notch1-targets should also be considered.
In summary, our results suggest that DLL4 expressed by
tumor microenvironment could activate Notch signaling in
CLL. In addition, we propose a functional link between
Notch1 signaling and aggressiveness-related protumor
processes in CLL, which could be disrupted by specific
Notch-targeting.
Materials and methods
Isolation and culture of cells
Primary cells from 20 CLL patients were studied (Table 1).
IGHV gene mutational status and NOTCH1 mutations were
analyzed in previous sequencing studies [2, 4, 5, 41]. Pri-
mary cells were isolated from peripheral blood by Ficoll-
Paque sedimentation (GE Healthcare, Little Chalfont, UK),
cryopreserved and conserved within the Hematopathology
collection of our institution registered at the Biobank from
Hospital Clínic-IDIBAPS (R121004-094). The ethical
approval for this project including the informed consent of
the patients was granted following the guidelines of the
Hospital Clínic Ethics Committee. Once thawed, cells were
cultured at 2 × 106 cells/ml in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS), 2 mM glutamine and
50 μg/ml penicillin-streptomycin (Life Technologies,
Carlsbad, CA, USA), in a humidified atmosphere at 37 °C
containing 5% carbon dioxide.
Notch ligand stimulation and cell treatment
Recombinant ligands Jagged1, Jagged2, DLL1, and DLL4
(R&D Systems, Minneapolis, MN, USA) were reconstituted
in phosphate buffered saline (PBS). Soluble ligands
(10 μg/ml for the experiments in Fig. 1 and 4 μg/ml for the
other experiments) were let to bind to 12-, 24- or 96-well
flat bottom polystyrene culture plates (Corning Inc., Corn-
ing, NY, USA) for 4 h at 4 °C after a spin down. Without
removing the excess of soluble ligands, CLL cells were
seeded in the previous plates and, after a centrifugation step,
the cultures were incubated for the indicated times. Two
hours before stimulation with ligands, CLL cells were
incubated with the anti-Notch1 antibody OMP-52M51
(kindly provided by Oncomed Pharmaceuticals, Redwood
City, CA, USA) at 25 μg/ml or with an isotype control.
Stromal cell lines OP9-DLL1 and -DLL4 cells were gen-
erated and grown as described [42]. For the generation of
OP9 stromal cell lines expressing human Jagged 1 (OP9-
JAG1), pLZRS-IRES-eGFP retroviral vectors encoding
either human Jag1 and GFP as cell tracer or only GFP were
kindly provided by Dr. L. Parreira (Instituto de Histologia e
Embriologia, Lisboa, Portugal). Jag1 and GFP retroviral
constructs were lipofected (Fugene6, Roche, Basel,
Switzerland) into 293T Phoenix-Amphotropic cells and
transfected cells were selected with 2.5 mg/ml puromycin
(Sigma-Aldrich, St. Louis, MO, USA) during two weeks.
Mouse OP9 BM stromal cells (American Type Culture
Collection; ATCC CRL-2749) were transduced by cen-
trifugation in the presence or 8 mg/ml polybrene. Forty
eight hours post transduction, OP9 cells were analyzed for
GFP expression by flow cytometry and sorted for homo-
geneous high expression of GFP. Quantification by flow
cytometry of the levels of JAG1, DLL1, and DLL4 con-
firmed that 100% of OP9-transfected cells expressed the
corresponding ligand (Supplemental Fig. 2).
For stroma cocultures, OP9 cells were plated overnight,
and then medium was replaced by CLL cells (2 × 106 cells/
mL) previously treated with OMP-52M51 for 2 h, or with
untreated cells. After 24 h of coculture, CLL cells were
collected by carefully rinsing the wells without disturbing
the stroma monolayer and processed as required.
Protein analysis
Protein extracts were obtained and processed by western
blot as previously described [43]. For protein immunode-
tection, the following specific primary antibodies were
used: cleaved Notch1 (Cell Signaling Technology, Danvers,
MA, USA) and β-actin (Sigma-Aldrich). Anti-rabbit and
anti-mouse horseradish peroxidase (HRP)-labeled IgGs
(Cell Signaling Technology) were used as secondary anti-
bodies. Chemiluminescence was detected with ECL sub-
strate (Pierce Biotechnology, Rockford, Il., USA) on a mini-
LAS4000 Fujifilm device (GE Healthcare). Signal was
quantified with Image Gauge densitometric software v4.0
(Fujifilm, Tokyo, Japan) and referred to the respective
control.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1194 M. López-Guerra et al.
Quantitative real-time PCR
Total RNA was isolated from CLL cells as previously [11].
cDNA was obtained from 0.5–1 μg of DNA-free RNA with
the M-MLV reverse transcriptase (Thermo Fisher Scientific,
Waltham, MA, USA). Samples were processed to Specific
Target Amplification using the Fluidigm PreAmpMaster
Mix (Fluidigm Corporation, San Francisco, CA, USA) and
the following TaqMan Gene Expression Assays (Thermo
Fisher Scientific): HES1, MYC, DTX1, CCND1, NRARP,
NPM1, CXCR4, and VEGFA. The relative expression of
each gene was quantified by the comparative cycle thresh-
old (Ct) method (ΔΔCt), using GUSB as endogenous con-
trol. To statistically address the effect of DLL4, no-ligand
control condition was used as a reference, and to address the
effect of OMP-52M51 on DLL4 stimulation, OMP-52M51
plus DLL4 condition was compared with DLL4 control
condition.
Immunohistochemistry and confocal microscopy
Lymph node biopsies from CLL cases were obtained from
the Hematopathology collection. Formalin-fixed paraffin-
embedded tissue slides (serial 8 μm sections) were depar-
affinised in xylene and etanol-graded series. Tissue antigens
were retrieved by boiling during 10–15 min in sodium
citrate (10 mM, pH 6.0) and slides were allowed to cool
down to room temperature (RT), and then washed in dis-
tilled water and PBS. Quenching and permeabilization were
carried out using 1% H2O2 in 100% methanol (40 min, RT)
and 0.3% Triton-X-100 (20 min, Sigma-Aldrich) in PBS,
respectively. Sections were incubated overnight with the
following primary antibodies: anti-human DLL4 (Rabbit,
Santa Cruz, Dallas, TX, USA) and anti-human CD68
(Dako, Glostrup, Germany). Background staining was
determined by incubating with irrelevant antibodies.
Unspecific fluorescence was quenched by incubating with
avidin/biotin blocking solutions (Vector Lab, Burlingame,
CA, USA). For DLL4 detection, tissue slides were incu-
bated with anti-rabbit IgG-HRP antibody (in 5% BSA in
PBS, Dako) and then, the signal was amplified by incuba-
tion with the Cyanine-3 Tyramide Signal Amplification Kit
(TSA; NEL 744, Perkin Elmer, Waltham, MA, USA). For
CD68 immunodetection, a biotinylated anti-mouse IgG
(Vector Lab) was added following incubation with avidin/
biotin complex (Elite Vectastain ABC Complex kit, Vector
Lab). Next, signal was developed by adding Alexa-488-
conjugated streptavidin. Nuclei were stained with Topro-3
(Invitrogen, Carlsbad, CA, USA) and mounted with
Fluoromount-G (Southern Biotech., Birmingham, AL,
USA). Images were acquired using a LSM510 laser scan
confocal microscope (Zeiss, Oberkochen, Germany) cou-
pled to an Axiovert 200 (Zeiss) microscope, using ×63
Plan-Neofluar magnification. Images were processed using
ImageJ and Adobe Photoshop CS3 software.
CFSE-based proliferation assay
CLL cells were stained with carboxyfluorescein diacetate
succinimidyl ester (CFSE; Thermo Fisher Scientific) as
described [16] with some modifications. Briefly, cells at
10 × 106/ml were incubated for 10 min in the dark with
0.5 μM CFSE. Then, an equal volume of FBS was added for
another 10 min and the cells were washed twice. CFSE-
labeled CLL cells were cultured in an enriched RPMI 1640
medium used for long-term cultures. Specifically, this
enriched medium contained 15% heat-inactivated FBS, 1X
ITS (insulin, transferrin, selenium cocktail; Biowhittaker,
Walkersville, MD, USA), 1 M pH7.3 HEPES, 1X non-
essential aminoacid solution (Thermofisher Scientific),
100 mM sodium pyruvate, 1X 2-mercaptoethanol (Ther-
mofisher Scientific) and 50 mg/mL gentamicin sulfate
(Biowhittaker). Recombinant human IL-15 (R&D Systems)
and the TLR9 ligand CpG oligonucleotide (ODN-2006;
Invivogen, San Diego, CA, USA) were added at final
concentrations of 15 ng/ml and 0.2 μM, respectively. After
6 days of incubation, cells were collected and stained with
Annexin-V-Pacific Blue (PB; Thermo Fisher Scientific) and
CD19-PE (Becton Dickinson, Franklin Lakes, NJ, USA)
and acquired in an Attune acoustic cytometer (Thermo
Fisher Scientific). CLL proliferation was measured as the
reduction on CFSE fluorescence based on the median
fluorescence intensity (MFI) on the CD19+ and Annexin-V
negative cell population. Data analysis was performed using
FlowJo v10.0.7 software (FlowJo, Ashland, OR, USA).
CXCR4 staining
CLL cells were stained with the Live/Dead® Fixable Aqua
Dead Cell Stain Kit (Life Technologies) and blocked with
10% mouse serum (Sigma). Then, samples were CXCR4-
PE or mouse IgG1 isotype- PE (Becton Dickinson) labeled
and acquired in an Attune acoustic cytometer (Thermo
Fisher Scientific). CXCR4 expression levels are showed
based on the MFI on viable cell population, using untreated
cells as a reference.
Chemotaxis assay
After 48 h of incubation with Notch ligands and OMP-
52M51, CLL cells were washed twice and serum starved for
1.5 h in FBS-free RPMI (107 cells/ml). One hundred μl of
diluted cells (5 × 106 cells/ml with 0.5% BSA in RPMI)
were added to the top chambers of transwell culture poly-
carbonate inserts with 6.5 mm diameter and 5 μm pore size
(Corning Inc.). Inserts had been previously transferred to
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wells containing 600 μl of 0.5% BSA in RPMI with
200 ng/ml of CXCL12 or 500 ng/ml of CXCL13. Total cell
count was obtained from adding 100 μl of cell suspension to
wells containing 600 μl of 0.5% BSA in RPMI. After 4 h,
100 μl were collected in triplicate from each lower chamber
and total wells, and viable cells were gated and counted on
an Attune cytometer (Thermo Fisher Scientific) under
constant flow rate. Migration was represented as percentage
of migrating cells out of total viable cells added to the
transwell.
HUVEC tube formation assay
HUVEC cells, kindly provided by Dr MC Cid (IDIBAPS),
were cultured as previously described [44]. Supernatant
from CLL cells (2 × 106 cells/ml) was harvested after 72 h
of incubation with OMP-52M51 and ligand stimulation.
Twenty-four-well plates were plated with 300 μl of Matrigel
(Becton Dickinson). Subsequently, 500 μl of the super-
natant of interest and 500 μl of HUVEC cells (0.8 × 105
cells/ml) were added into each culture well. For the control,
the supernatant was substituted for complete RPMI med-
ium. After 24 h of incubation, the number of branch points
was counted and quantified as the mean of five randomly
chosen fields from each well. Pictures were taken at ×40
magnification in a DM IL LED microscope (Leica, Solms,
Germany) coupled to a DFC295 camera with Leica Appli-
cation Suite v3.7 software (Leica).
Statistical analyses
Data are represented as mean ± SEM of all cases. Statistics
were calculated using GraphPadPrism 4.0 software (Graph-
Pad Software, La Jolla, CA, USA). Nonparametric Wilcoxon
signed rank test was used to compare the median of a set of
samples to a theoretical value. Comparison between means
of two sets of samples was evaluated by nonparametric
Wilcoxon matched-pairs test or Mann–Whitney test. Results
were considered statistically significant when p-value < 0.05
(*p < 0.05, **p < 0.01, ***p < 0.001).
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